They reported 50% true-positive bone lesions with the [18F]rhPSMA-7.3; this is quite significant as it can alter management, the reported sensitivity for bone metastatic disease detection is variable ranging from 6–60% as published in a recent meta-analysis for [ 68 Ga]Ga-PSMA-11 ( 9 ).
← all excerpts
Radiohybrid prostate-specific membrane antigen ligand: new frontier in prostate cancer imaging and therapy.
1
—
—